Lai Kai Pharmaceutical-B (02105) rose more than 12%, and as of press time, it rose 10.9%, to HKD 5.9, with a turnover of HKD 4.324 million.
According to the financial news app, Lai Kai Pharmaceutical-B (02105) rose by more than 12%, and as of press time, it rose 10.9%, to HKD 5.9, with a turnover of HKD 4.324 million.
On the news side, Lai Kai Pharmaceuticals announced last month that after obtaining FDA clinical trial approval for new drugs in the United States, its independently developed LAE102 (ActRIIA monoclonal antibody) has been approved by the National Drug Administration's Drug Evaluation Center for clinical trials, which can be used to treat obese patients. The company is accelerating the preparation of phase I clinical trials. It is reported that in recent years, GLP-1 targeted weight loss drugs headed by semaglutide have swept the entire market. In 2024, the heat of weight loss drugs remains high. The continuous rise in performance of Novo Nordisk and Eli Lilly is due to the surge in demand for weight loss drugs in the market.
In addition, Pacific Securities pointed out that the company's core pipeline will have multiple catalysts in 2024. Lai Kai Pharmaceuticals previously announced that the phase III clinical trial AFFIRM-205 of LAE 002 (afuresertib, an oral AKT inhibitor) combined with fluvisatinib for HR+/HER2-negative locally advanced or metastatic breast cancer (LA/mBC) with PIK3CA/AKT1/PTEN mutations has been initiated in China, and patient recruitment has been completed for the first case.